Clinical trials: Renal Cell Carcinoma
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Malignant Melanoma, Non-small Cell Lung Cancer
ImmuniCell® in Patients With Advanced Cancers
To determine the safety, tolerability, maximum tolerated dose (MTD) and efficacy of ImmuniCell® in patients with melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC).
- Conditions
- Malignant Melanoma, Non-small Cell Lung Cancer, Renal Cell Cancer
- Trial name
- NCT02459067
- Testing
- ImmuniCell®
- Where
- 7 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- TC Biopharm
Colorectal Cancer, Ovarian Cancer
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response.
- Conditions
- Colorectal Cancer, Ovarian Cancer, Gastric Cancer, Breast Cancer
- Trial name
- NCT00722228
- Testing
- Autologous or Allogeneic tumor cells
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
A Study of Oncobax®-AK in Patients With Advanced Solid Tumors
Akkermansia muciniphila is a naturally occurring bacterium found in the healthy human gastrointestinal tract. Analysis of the gut microbiota of NSCLC or RCC patients shows that the presence of Akkermansia is associated with the…
- Trial name
- NCT05865730
- Testing
- Live Bacterial Product - Akkermansia muciniphila
- Where
- 4 sites in Belgium, France
- Volunteers
- 122 people
- Sponsor
- EverImmune
Bladder Transitional Cell Carcinoma Stage IV
JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
This study is assessing the combination of well known cytotoxics with a novel anti-cancer agent that could be administered as monotherapy without renal toxicity in patients with renal impairment presenting with advanced or…
- Trial name
- JASINT1 (NCT01599013)
- Testing
- Vinflunine, Gemcitabine, Vinflunine, Carboplatin
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Pierre Fabre Medicament
Kidney Cancer
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00853125
- Testing
- therapeutic allogeneic lymphocytes, sunitinib malate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rutgers, The State University of New Jersey
Renal Cell Carcinoma
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
This study will generate safety data on Nivolumab given by itself in treatment of advanced Renal Cell Carcinoma (RCC). The primary objective of this study is to assess immune related side effects, also known as immune-mediated…
- Trial name
- CheckMate 374 (NCT02596035)
- Testing
- Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
The study aims to assess antineoplastic efficacy, safety, influence on quality of life and disease-related stress of propranolol taken in combination with sunitinib in previously untreated metastatic renal cell carcinoma
- Trial name
- NCT03323710
- Testing
- Propranolol, Sunitinib
- Where
- Poland
- Sponsor
- Military Institute od Medicine National Research Institute
Renal Carcinoma
Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients
This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell…
- Trial name
- RASROP-003 (NCT07465458)
- Testing
- Radiofrequency Ablation (RFA)
- Where
- 10 sites in Italy, Spain
- Volunteers
- 226 people
- Sponsor
- Humanitas Hospital, Italy
Clear Cell Renal Cell Carcinoma
68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion
This is a prospective, single-center, single-arm phase 2 study in patients with clear cell renal cell carcinoma and metastasis or recurrence suspicion.
- Trial name
- NCT05879497
- Testing
- 68Ga-NY104 PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with advanced or metastatic…
- Trial name
- NCT00066352
- Testing
- bortezomib
- Where
- 15 sites in United States, Canada
- Sponsor
- University Health Network, Toronto
Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma
This phase III trial compares the effect of pembrolizumab to active surveillance after a surgical procedure to completely or partially remove a kidney (nephrectomy) in improving time without disease in patients with non-clear…
- Conditions
- Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT07689240
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Volunteers
- 400 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
The TORAVA trial is designed to evaluate the progression-free rate at 48 weeks of a combination of Torisel® and Avastin® given at first-line treatment in patients with metastatic renal cancer.
- Trial name
- TORAVA (NCT00619268)
- Testing
- Temsirolimus, Bevacizumab, Sunitinib
- Where
- 29 sites in France
- Volunteers
- 160 people
- Sponsor
- Centre Leon Berard
Chronic Myeloproliferative Disorders, Kidney Cancer
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00295997
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Clear Cell Renal Cell Carcinoma
89Zr-DFO-girentuximab Expanded Access Program (EAP)
The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9…
- Trial name
- NCT06090331
- Testing
- 89Zr-DFO-girentuximab
- Where
- 22 sites in United States
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Renal Cell Carcinoma, Kidney Neoplasm
Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
The aim of this study is to gain a better understanding of the phenomenon of adherent perinephric fat (APF), which occurs in some patients undergoing partial nephrectomy (PN).
- Conditions
- Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms, Urogenital Neoplasms
- Trial name
- NCT05887245
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Centre of Postgraduate Medical Education
Solid Tumor, Adult
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018).
- Trial name
- NCT05230186
- Testing
- Tumor Biopsy
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- TScan Therapeutics, Inc.
Renal Carcinoma Metastatic, Kidney Neoplasms
Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma
Physician mainly use RECIST progression-free survival (PFS) and NCI CTCAE safety as a guide to evaluate treatment efficiency. In contrast Health Related Quality of Life (HRQOL) assessment is often restricted to clinical trial.
- Conditions
- Renal Carcinoma Metastatic, Kidney Neoplasms, Renal Cancer
- Trial name
- QUANARIE (NCT03062410)
- Testing
- Electronic PRO in daily clinical practice
- Where
- 8 sites in France
- Volunteers
- 56 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.